- Email: [email protected]
Detailed overview on the mutations detected by and the sensitivity of the GeneReader NGS sequencing platform
Data in Brief 18 (2018) 1962–1966
Contents lists available at ScienceDirect
Data in Brief journal homepage: www.elsevier.com/locate/dib
Data article
Detailed overview on the mutations detected by and the sensitivity of the GeneReader NGS sequencing platform Jessica Lüsebrink, Monika Pieper, Ramona-Liza Tillmann, Michael Brockmann, Oliver Schildgen, Verena Schildgen n Kliniken der Stadt Köln gGmbH, Klinikum der Privaten Universität Witten/Herdecke mit Sitz in Köln, Institut für Pathologie, Ostmerheimer Str. 200, D-51109 Köln/Cologne, Germany
a r t i c l e i n f o
abstract
Article history: Received 3 April 2018 Received in revised form 13 April 2018 Accepted 27 April 2018 Available online 4 May 2018
This article presents additional next generation data from our preclinical validation study. In total 121 samples (clinical specimen and interlaboratory test samples) were tested successfully with next generation sequencing. 38 different mutations in six different genes were detected. Next to the detection of different mutations, the reproducibility of the NGS test was analyzed. Three samples were analyzed five times and the results were compared. Several mutations classified as non-pathogenic so far, have been detected repeatedly. & 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Specifications table Subject area More specific subject area Type of data How data was acquired Data format
n
Biology Genetics Tables Next Generation Sequencing analyzed
DOI of original article: https://doi.org/10.1016/j.yexmp.2018.04.001 Corresponding author. E-mail addresses: [email protected] (O. Schildgen), [email protected] (V. Schildgen).
https://doi.org/10.1016/j.dib.2018.04.114 2352-3409/& 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
J. Lüsebrink et al. / Data in Brief 18 (2018) 1962–1966
Experimental factors Experimental features
Data source location Data accessibility
1963
DNA was extracted from FFPE-tumor samples and interlaboratory test samples for further analysis Next Generation Sequencing was performed to determine the presence of pathogenic mutations, which have an impact on therapeutic decisions Cologne, Germany with this article
Value of the data
Common and rare mutations were detected, information on rare mutations could be of interest for further studies on specific mutations.
Many mutations classified as non-pathogenic are detected alongside the analysis of pathogenic mutations, impact of those alterations on therapy is not fully known so far.
Repeatability of the assay is given also for non-pathogenic mutations.
1. Data The data represented here is additional data from our pre-clinical validation study (1). Table 1 shows the mutations, which were detected by NGS in the samples used for a clinical pre-validation in our laboratory. In total 107 pathogenic mutations were detected in the 121 samples tested successfully. 38 different mutations were detected: 4 different mutations in BRAF, 12 in EGFR, 2 in KIT, 9 in KRAS, 5 in NRAS, and 6 in PIK3CA. Common mutations as KRAS c.35G4A (p.G12D), BRAF c.1799T 4A (p.V600E) or EGFR c.2573T 4G (p.L858R) could be detected as well as more uncommon mutations (e.g. KRAS c.351A 4T (p.K117N) or NRAS c.437C4 T (p.A146V)). Table 2 shows mutations, classified as non-pathogenic so far, which were detected in samples used for the testing of the repeatability of the GeneRead QIAact Actionable Insights Tumor Panel. 24 genetic alterations were detected in the Multiplex reference standard; nine respectively eight alterations were detected in the two clinical samples. Except for one mutation, which had a percentage of a mutant (PM) in the background of wild type in the range of the limit of detection, all mutations could be detected with similar frequencies in all five repetitions.
2. Experimental design, materials and methods 122 samples were tested retrospectively to validate the use of the GeneReader System in our laboratory. One sample proofed to be not suitable for NGS testing and was excluded from the analysis. The GeneRead QIAact Actionable Insights Tumor Panel was used for target enrichment of ALK, BRAF, EGFR, ERBB2, ERBB3, ESR1, KIT, KRAS, NRAS, PDGFRA, PIK3CA, and RAF1. Following target enrichment, library preparation and clonal amplification was done using the GeneRead DNA Library Q Kit and the GeneRead Clonal Amp Q Kit. DNA quality and concentration was determined after target enrichment and library preparation with the QIAxcel DNA High Resolution Kit on the QIAxcel instrument. Sequencing was performed on the GeneReader instrument with the GeneRead Sequencing Q Kit. Qiagen Clinical Insight Software was used for analysis and interpretation of the results. Sequencing products are analyzed by comparison with the following reference sequences: NM_004304.4 (ALK), NM_004333.4 (BRAF), NM_005228.4 (EGFR), NM_004448.3 (ERBB2), NM_001982.3 (ERBB3), NM_001122742.1 (ESR1), NM_000222.2 (KIT), NM_004985.4 (KRAS), NM_002524.4 (NRAS), NM_006206.5 (PDGFRA), NM_006218.3 (PIK3CA), and NM_002880.3 (RAF1).
1964
J. Lüsebrink et al. / Data in Brief 18 (2018) 1962–1966
Table 1 Detected mutations. The table shows the mutations which were detected by NGS in the tested samples. Mutations were detected in BRAF, EGFR, KIT, KRAS, NRAS, and PIK3CA. Gene Total BRAF
Nucleotide substitution/ Amino Acid substitution
Total c.1397G4 C/ p.G466A c.1406G 4C/ p.G469A c.1799T 4A/ p.V600E c.1798_1799delGTinsAA/ p.V600K EGFR Total c.2127_2129delAAC/ p.E709_T710delinsD c.2156G 4C/ p.G719A c.2254_227delTCTCC/ p.S725_I759del c.2222C 4T/ p.P741L c.2237_2255delAATTAAGAGAAGCAACATCinsT/ p. E746_S752delinsV c.2235_2249delGGAATTAAGAGAAGC/ p.E746_A750del c.2248G 4C/ p.A750P c.2281G 4A/ p.D761N c.2369C 4T/ p.T790M c.2573T 4G/ p.L858R c.2582T 4A/ p.L861Q c.2596G 4A/ p.E866K KIT Total c.1509_1510insGCCTAT/ p.Y503_F504insAY c.2447A 4T/p.D816V KRAS Total c.34G 4A/ p.G12S c.34G 4T/ p.G12C c.35G4 A/ p.G12D c.35G4 C/ p.G12A c.35G4 T/ p.G12V c.38G 4A/ p.G13D c.183A 4T/ p.Q61H c.351A 4 T/ p.K117N c.436G 4A/ p.A146T NRAS Total c.35G4 A/ p.G12D c.181C4 A/ p.Q61K c.182A 4G/ p.Q61R c.182A 4T/ p.Q61L c.437C 4T/ p.A146V PIK3CA Total c.1633G4A/ p.E545K c.317_318delGCinsTT/ p.G106V c.331A 4G/ p.K111E c.3140A 4G/ p.H1047R c.3129G 4T/ p.M1043I c.263G 4A/ p.R88Q
Total % 107 18 1 1 13 3 39 1 1 1 1 3
Clinical specimen 100 44 16,82 7 0,93 1 0,93 1 12,15 4 2,80 1 36,45 10 0,93 – 0,93 1 0,93 1 0,93 1 2,80 1
Interlaboratory test samples 63 11 – – 9 2 29 1 – – – 2
3 1 1 12 11 1 1 2 1 1 29 1 2 4 2 9 4 4 1 2 9 1 1 1 5 1 10 5 1 1 1 1 1
2,80 0,93 0,93 11,21 10,28 0,93 0,93 1,87 0,93 0,93 27,10 0,93 1,87 3,74 1,87 8,41 3,74 3,74 0,93 1,87 8,41 0,93 0,93 0,93 4,67 0,93 9,35 4,67 0,93 0,93 0,93 0,93 0,93
– 1 1 11 11 – – 1 – 1 10 1 – – 1 3 2 2 – 1 6 1 1 – 4 – 6 3 – – 1 1 1
3 – – 1 – 1 1 1 1 – 19 – 2 4 1 6 2 2 1 1 3 – – 1 1 1 4 2 1 1 – – –
Table 2 Non-pathogenic mutations detected with NGS in samples used to determine the precision. Several alterations not known to have therapeutically impact so far were detected with NGS. Sample
Multiplex reference standard
Tumor sample 2
c.2535T4C/ p.G845G c.3036G 4A/ p.T1012T c.4338C 4T/ p.T1446T c.4472A4G/ p.K1491R c.1929A 4G/ p.G643G c.1968C 4T/ p.H656H c.474C4 T/ p.N158N c.2361G4A/ p.Q787Q c.1963A 4G/ p.I655V c.3508C 4G/ p.P1170A c.3355A4T/ p.S1119C c.1369 þ13777T4 G c.30T 4C/ p.S10S c.2362-77G4 A c.2586G 4C/ p.L862L c.1432T 4C/ p.S478P c.1701A 4G/ p.P567P c.1809G 4 A/ p.A603A c.2472C 4T/ p.V824V c.612T4 C/ p.N204N c.939T4 G/ p.G313G c.-76-14537C 4G c.-77þ 8483C 4T c.1173A4 G/ p.I391M c.*2505T 4G c.2535T4C/ p.G845G c.4472A4G/ p.K1491R c.2361G4A/ p.Q787Q c.474C4 T/ p.N158N c.2184þ 19G4A c.1881-781C 4T c.3508C 4G/ p.P1170A c.1701A 4G/ p.P567P c.2535T4C/ p.G845G c.4472A4G/ p.K1491R c.474C4 T/ p.N158N c.2361G4A/ p.Q787Q c.3508C 4G/ p.P1170A c.30T 4C/ p.S10S c.2362-77G4 A c.1701A 4G/ p.P567P
Repetition 1
Repetition 2
Repetition 3
Repetition 4
Repetition 5
82 12 33 12 18 8,64 80 14 37 20 34 10 16 32 8,36 8,85 100 20 18 9,2 8,71 49 6,72 10 47 44 58 47 50 4,96 49 51 100 47 43 41 99 47 99 34 100
80 7,34 31 11 19 6,78 79 16 33 18 34 8,77 21 35 8,7 9,44 100 17 15 8,68 7,99 50 7,54 6,49 47 43 56 51 49 – 54 52 100 47 46 40 99 47 100 33 100
84 12 33 10 21 6,02 78 16 33 16 30 13 24 30 8,99 8,61 100 15 14 10 8,88 49 7,09 8,08 46 43 57 52 51 5,5 50 46 99 45 43 45 98 46 100 36 100
84 10 30 11 21 7 80 16 34 19 30 9 9 31 9,23 8,09 100 17 15 8,91 8,64 54 7,5 11 50 44 55 48 53 – 49 53 98 41 47 44 99 51 100 34 100
83 12 34 8,98 20 5,95 81 15 33 22 33 10 8,79 29 9,3 8,2 100 17 20 8,34 10 48 7,3 10 51 44 58 48 50 – 50 48 99 43 46 42 99 46 100 37 100
Mean
SD
82,60 10,67 32,20 10,60 19,80 6,88 79,60 15,40 34,00 19,00 32,20 10,15 15,76 31,40 8,92 8,64 100,00 17,20 16,40 9,03 8,84 50,00 7,23 9,11 48,20 43,60 56,80 49,20 50,60 5,23 50,40 50,00 99,20 44,60 45,00 42,40 98,80 47,40 99,80 34,80 100,00
1,50 1,84 1,47 1,03 1,17 0,97 1,02 0,80 1,55 2,00 1,83 1,51 6,16 2,06 0,35 0,49 0,00 1,60 2,24 0,56 0,65 2,10 0,30 1,62 1,94 0,49 1,17 1,94 1,36 0,27 1,85 2,61 0,75 2,33 1,67 1,85 0,40 1,85 0,40 1,47 0,00
1965
ALK ALK ALK ALK BRAF EGFR EGFR EGFR ERBB2 ERBB2 ERBB3 ESR1 ESR1 KIT KIT PDGFRA PDGFRA PDGFRA PDGFRA PDGFRA PDGFRA PIK3CA PIK3CA PIK3CA KRAS ALK ALK EGFR EGFR EGFR EGFR ERBB2 PDGFRA ALK ALK EGFR EGFR ERBB2 ESR1 KIT PDGFRA
Detected frequency of mutation [%]
J. Lüsebrink et al. / Data in Brief 18 (2018) 1962–1966
Tumor sample 1
Mutation
1966
J. Lüsebrink et al. / Data in Brief 18 (2018) 1962–1966
Transparency document. Supporting information Supplementary data associated with this article can be found in the online version at doi:10.1016/j. dib.2018.04.114.
Further reading [1] J. Lüsebrink, M. Pieper, R.L. Tillmann, M. Brockmann, O. Schildgen, V. Schildgen, Pre-clinical validation of a next generation sequencing testing panel, Exp. Mol. Pathol. (2018), http://dx.doi.org/10.1016/j.yexmp.2018.04.001 (Epub ahead of print)( PMID:29641993) (pii: S0014–4800(17)(30602-0).
Contents lists available at ScienceDirect
Data in Brief journal homepage: www.elsevier.com/locate/dib
Data article
Detailed overview on the mutations detected by and the sensitivity of the GeneReader NGS sequencing platform Jessica Lüsebrink, Monika Pieper, Ramona-Liza Tillmann, Michael Brockmann, Oliver Schildgen, Verena Schildgen n Kliniken der Stadt Köln gGmbH, Klinikum der Privaten Universität Witten/Herdecke mit Sitz in Köln, Institut für Pathologie, Ostmerheimer Str. 200, D-51109 Köln/Cologne, Germany
a r t i c l e i n f o
abstract
Article history: Received 3 April 2018 Received in revised form 13 April 2018 Accepted 27 April 2018 Available online 4 May 2018
This article presents additional next generation data from our preclinical validation study. In total 121 samples (clinical specimen and interlaboratory test samples) were tested successfully with next generation sequencing. 38 different mutations in six different genes were detected. Next to the detection of different mutations, the reproducibility of the NGS test was analyzed. Three samples were analyzed five times and the results were compared. Several mutations classified as non-pathogenic so far, have been detected repeatedly. & 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Specifications table Subject area More specific subject area Type of data How data was acquired Data format
n
Biology Genetics Tables Next Generation Sequencing analyzed
DOI of original article: https://doi.org/10.1016/j.yexmp.2018.04.001 Corresponding author. E-mail addresses: [email protected] (O. Schildgen), [email protected] (V. Schildgen).
https://doi.org/10.1016/j.dib.2018.04.114 2352-3409/& 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
J. Lüsebrink et al. / Data in Brief 18 (2018) 1962–1966
Experimental factors Experimental features
Data source location Data accessibility
1963
DNA was extracted from FFPE-tumor samples and interlaboratory test samples for further analysis Next Generation Sequencing was performed to determine the presence of pathogenic mutations, which have an impact on therapeutic decisions Cologne, Germany with this article
Value of the data
Common and rare mutations were detected, information on rare mutations could be of interest for further studies on specific mutations.
Many mutations classified as non-pathogenic are detected alongside the analysis of pathogenic mutations, impact of those alterations on therapy is not fully known so far.
Repeatability of the assay is given also for non-pathogenic mutations.
1. Data The data represented here is additional data from our pre-clinical validation study (1). Table 1 shows the mutations, which were detected by NGS in the samples used for a clinical pre-validation in our laboratory. In total 107 pathogenic mutations were detected in the 121 samples tested successfully. 38 different mutations were detected: 4 different mutations in BRAF, 12 in EGFR, 2 in KIT, 9 in KRAS, 5 in NRAS, and 6 in PIK3CA. Common mutations as KRAS c.35G4A (p.G12D), BRAF c.1799T 4A (p.V600E) or EGFR c.2573T 4G (p.L858R) could be detected as well as more uncommon mutations (e.g. KRAS c.351A 4T (p.K117N) or NRAS c.437C4 T (p.A146V)). Table 2 shows mutations, classified as non-pathogenic so far, which were detected in samples used for the testing of the repeatability of the GeneRead QIAact Actionable Insights Tumor Panel. 24 genetic alterations were detected in the Multiplex reference standard; nine respectively eight alterations were detected in the two clinical samples. Except for one mutation, which had a percentage of a mutant (PM) in the background of wild type in the range of the limit of detection, all mutations could be detected with similar frequencies in all five repetitions.
2. Experimental design, materials and methods 122 samples were tested retrospectively to validate the use of the GeneReader System in our laboratory. One sample proofed to be not suitable for NGS testing and was excluded from the analysis. The GeneRead QIAact Actionable Insights Tumor Panel was used for target enrichment of ALK, BRAF, EGFR, ERBB2, ERBB3, ESR1, KIT, KRAS, NRAS, PDGFRA, PIK3CA, and RAF1. Following target enrichment, library preparation and clonal amplification was done using the GeneRead DNA Library Q Kit and the GeneRead Clonal Amp Q Kit. DNA quality and concentration was determined after target enrichment and library preparation with the QIAxcel DNA High Resolution Kit on the QIAxcel instrument. Sequencing was performed on the GeneReader instrument with the GeneRead Sequencing Q Kit. Qiagen Clinical Insight Software was used for analysis and interpretation of the results. Sequencing products are analyzed by comparison with the following reference sequences: NM_004304.4 (ALK), NM_004333.4 (BRAF), NM_005228.4 (EGFR), NM_004448.3 (ERBB2), NM_001982.3 (ERBB3), NM_001122742.1 (ESR1), NM_000222.2 (KIT), NM_004985.4 (KRAS), NM_002524.4 (NRAS), NM_006206.5 (PDGFRA), NM_006218.3 (PIK3CA), and NM_002880.3 (RAF1).
1964
J. Lüsebrink et al. / Data in Brief 18 (2018) 1962–1966
Table 1 Detected mutations. The table shows the mutations which were detected by NGS in the tested samples. Mutations were detected in BRAF, EGFR, KIT, KRAS, NRAS, and PIK3CA. Gene Total BRAF
Nucleotide substitution/ Amino Acid substitution
Total c.1397G4 C/ p.G466A c.1406G 4C/ p.G469A c.1799T 4A/ p.V600E c.1798_1799delGTinsAA/ p.V600K EGFR Total c.2127_2129delAAC/ p.E709_T710delinsD c.2156G 4C/ p.G719A c.2254_227delTCTCC/ p.S725_I759del c.2222C 4T/ p.P741L c.2237_2255delAATTAAGAGAAGCAACATCinsT/ p. E746_S752delinsV c.2235_2249delGGAATTAAGAGAAGC/ p.E746_A750del c.2248G 4C/ p.A750P c.2281G 4A/ p.D761N c.2369C 4T/ p.T790M c.2573T 4G/ p.L858R c.2582T 4A/ p.L861Q c.2596G 4A/ p.E866K KIT Total c.1509_1510insGCCTAT/ p.Y503_F504insAY c.2447A 4T/p.D816V KRAS Total c.34G 4A/ p.G12S c.34G 4T/ p.G12C c.35G4 A/ p.G12D c.35G4 C/ p.G12A c.35G4 T/ p.G12V c.38G 4A/ p.G13D c.183A 4T/ p.Q61H c.351A 4 T/ p.K117N c.436G 4A/ p.A146T NRAS Total c.35G4 A/ p.G12D c.181C4 A/ p.Q61K c.182A 4G/ p.Q61R c.182A 4T/ p.Q61L c.437C 4T/ p.A146V PIK3CA Total c.1633G4A/ p.E545K c.317_318delGCinsTT/ p.G106V c.331A 4G/ p.K111E c.3140A 4G/ p.H1047R c.3129G 4T/ p.M1043I c.263G 4A/ p.R88Q
Total % 107 18 1 1 13 3 39 1 1 1 1 3
Clinical specimen 100 44 16,82 7 0,93 1 0,93 1 12,15 4 2,80 1 36,45 10 0,93 – 0,93 1 0,93 1 0,93 1 2,80 1
Interlaboratory test samples 63 11 – – 9 2 29 1 – – – 2
3 1 1 12 11 1 1 2 1 1 29 1 2 4 2 9 4 4 1 2 9 1 1 1 5 1 10 5 1 1 1 1 1
2,80 0,93 0,93 11,21 10,28 0,93 0,93 1,87 0,93 0,93 27,10 0,93 1,87 3,74 1,87 8,41 3,74 3,74 0,93 1,87 8,41 0,93 0,93 0,93 4,67 0,93 9,35 4,67 0,93 0,93 0,93 0,93 0,93
– 1 1 11 11 – – 1 – 1 10 1 – – 1 3 2 2 – 1 6 1 1 – 4 – 6 3 – – 1 1 1
3 – – 1 – 1 1 1 1 – 19 – 2 4 1 6 2 2 1 1 3 – – 1 1 1 4 2 1 1 – – –
Table 2 Non-pathogenic mutations detected with NGS in samples used to determine the precision. Several alterations not known to have therapeutically impact so far were detected with NGS. Sample
Multiplex reference standard
Tumor sample 2
c.2535T4C/ p.G845G c.3036G 4A/ p.T1012T c.4338C 4T/ p.T1446T c.4472A4G/ p.K1491R c.1929A 4G/ p.G643G c.1968C 4T/ p.H656H c.474C4 T/ p.N158N c.2361G4A/ p.Q787Q c.1963A 4G/ p.I655V c.3508C 4G/ p.P1170A c.3355A4T/ p.S1119C c.1369 þ13777T4 G c.30T 4C/ p.S10S c.2362-77G4 A c.2586G 4C/ p.L862L c.1432T 4C/ p.S478P c.1701A 4G/ p.P567P c.1809G 4 A/ p.A603A c.2472C 4T/ p.V824V c.612T4 C/ p.N204N c.939T4 G/ p.G313G c.-76-14537C 4G c.-77þ 8483C 4T c.1173A4 G/ p.I391M c.*2505T 4G c.2535T4C/ p.G845G c.4472A4G/ p.K1491R c.2361G4A/ p.Q787Q c.474C4 T/ p.N158N c.2184þ 19G4A c.1881-781C 4T c.3508C 4G/ p.P1170A c.1701A 4G/ p.P567P c.2535T4C/ p.G845G c.4472A4G/ p.K1491R c.474C4 T/ p.N158N c.2361G4A/ p.Q787Q c.3508C 4G/ p.P1170A c.30T 4C/ p.S10S c.2362-77G4 A c.1701A 4G/ p.P567P
Repetition 1
Repetition 2
Repetition 3
Repetition 4
Repetition 5
82 12 33 12 18 8,64 80 14 37 20 34 10 16 32 8,36 8,85 100 20 18 9,2 8,71 49 6,72 10 47 44 58 47 50 4,96 49 51 100 47 43 41 99 47 99 34 100
80 7,34 31 11 19 6,78 79 16 33 18 34 8,77 21 35 8,7 9,44 100 17 15 8,68 7,99 50 7,54 6,49 47 43 56 51 49 – 54 52 100 47 46 40 99 47 100 33 100
84 12 33 10 21 6,02 78 16 33 16 30 13 24 30 8,99 8,61 100 15 14 10 8,88 49 7,09 8,08 46 43 57 52 51 5,5 50 46 99 45 43 45 98 46 100 36 100
84 10 30 11 21 7 80 16 34 19 30 9 9 31 9,23 8,09 100 17 15 8,91 8,64 54 7,5 11 50 44 55 48 53 – 49 53 98 41 47 44 99 51 100 34 100
83 12 34 8,98 20 5,95 81 15 33 22 33 10 8,79 29 9,3 8,2 100 17 20 8,34 10 48 7,3 10 51 44 58 48 50 – 50 48 99 43 46 42 99 46 100 37 100
Mean
SD
82,60 10,67 32,20 10,60 19,80 6,88 79,60 15,40 34,00 19,00 32,20 10,15 15,76 31,40 8,92 8,64 100,00 17,20 16,40 9,03 8,84 50,00 7,23 9,11 48,20 43,60 56,80 49,20 50,60 5,23 50,40 50,00 99,20 44,60 45,00 42,40 98,80 47,40 99,80 34,80 100,00
1,50 1,84 1,47 1,03 1,17 0,97 1,02 0,80 1,55 2,00 1,83 1,51 6,16 2,06 0,35 0,49 0,00 1,60 2,24 0,56 0,65 2,10 0,30 1,62 1,94 0,49 1,17 1,94 1,36 0,27 1,85 2,61 0,75 2,33 1,67 1,85 0,40 1,85 0,40 1,47 0,00
1965
ALK ALK ALK ALK BRAF EGFR EGFR EGFR ERBB2 ERBB2 ERBB3 ESR1 ESR1 KIT KIT PDGFRA PDGFRA PDGFRA PDGFRA PDGFRA PDGFRA PIK3CA PIK3CA PIK3CA KRAS ALK ALK EGFR EGFR EGFR EGFR ERBB2 PDGFRA ALK ALK EGFR EGFR ERBB2 ESR1 KIT PDGFRA
Detected frequency of mutation [%]
J. Lüsebrink et al. / Data in Brief 18 (2018) 1962–1966
Tumor sample 1
Mutation
1966
J. Lüsebrink et al. / Data in Brief 18 (2018) 1962–1966
Transparency document. Supporting information Supplementary data associated with this article can be found in the online version at doi:10.1016/j. dib.2018.04.114.
Further reading [1] J. Lüsebrink, M. Pieper, R.L. Tillmann, M. Brockmann, O. Schildgen, V. Schildgen, Pre-clinical validation of a next generation sequencing testing panel, Exp. Mol. Pathol. (2018), http://dx.doi.org/10.1016/j.yexmp.2018.04.001 (Epub ahead of print)( PMID:29641993) (pii: S0014–4800(17)(30602-0).